Dyadic International, Inc. (NASDAQ:DYAI) is a global biotechnology company. The Company focuses on improving and applying the proprietary C1 expression system to help drug developers and manufacturers bring biologic drugs to market.
Dyadic (NASDAQ:DYAI) President and CEO Mark Emalfarb joined Steve Darling from Proactive Vancouver with news the company continues to very busy even with the COVID-19 crisis. Emalfarb discussing what the company is doing with other partners to help battle the virus. Emalfarb also telling Proactive about a deal they signed with a major biological company WuXi.
The world might need billions of doses of low cost, effective vaccines against the #COVID-19 virus, It’s time to think outside the box, as Einstein has ben quoted it’s insanity to do the same thing over and over again and expect different results.
